Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study

The present randomized, double-blind, placebo-controlled, 2-year study is the first to evaluate the effect of 1.25 and 2.5 mg tibolone daily oral administration on trabecular and cortical bone loss in early postmenopausal women

B. Berning

2002

Scholarcy highlights

  • The present randomized, double-blind, placebo-controlled, 2-year study is the first to evaluate the effect of 1.25 and 2.5 mg tibolone daily oral administration on trabecular and cortical bone loss in early postmenopausal women
  • Twenty-three subjects were randomized to the placebo group, 36 to the 1.25 mg/day tibolone group, and 35 to the 2.5 mg/day tibolone group
  • Bone density was assessed at 6 month intervals
  • Phalangeal cortical bone density was measured by radiographic absorptiometry
  • After 2 years of tibolone in both regimes, trabecular and phalangeal BD was significantly higher as compared to pretreatment values
  • Tibolone prevents early post-menopausal bone loss by inducing an increase in trabecular and phalangeal bone density

Need more features? Save interactive summary cards to your Scholarcy Library.